Alex Hemeryck

1.0k total citations
15 papers, 784 citations indexed

About

Alex Hemeryck is a scholar working on Oncology, Pharmacology and Hematology. According to data from OpenAlex, Alex Hemeryck has authored 15 papers receiving a total of 784 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 4 papers in Pharmacology and 4 papers in Hematology. Recurrent topics in Alex Hemeryck's work include Pharmacogenetics and Drug Metabolism (4 papers), Analytical Methods in Pharmaceuticals (3 papers) and Multiple Myeloma Research and Treatments (2 papers). Alex Hemeryck is often cited by papers focused on Pharmacogenetics and Drug Metabolism (4 papers), Analytical Methods in Pharmaceuticals (3 papers) and Multiple Myeloma Research and Treatments (2 papers). Alex Hemeryck collaborates with scholars based in Belgium, United States and Netherlands. Alex Hemeryck's co-authors include Frans M. Belpaire, R A Lefebvre, Sofie Poelmans, Judith Baumeister, Juan José Pérez Ruixo, Maarten Van Roy, Joost A. Kolkman, Cedric Ververken, Michel Vierboom and Hans Ulrichts and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Biochemical Pharmacology and Journal of Pharmaceutical Sciences.

In The Last Decade

Alex Hemeryck

15 papers receiving 753 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alex Hemeryck Belgium	12	220	204	139	134	120	15	784
Edgar Hänseler Switzerland	18	211 1.0×	173 0.8×	202 1.5×	99 0.7×	40 0.3×	45	913
Junko Ishizaki Japan	18	213 1.0×	154 0.8×	110 0.8×	278 2.1×	44 0.4×	61	931
Phillip A. Reece Australia	17	246 1.1×	96 0.5×	106 0.8×	164 1.2×	26 0.2×	36	886
Gershwin T. Blyden United States	12	125 0.6×	148 0.7×	111 0.8×	98 0.7×	35 0.3×	30	691
Nancy Van Osselaer Belgium	18	207 0.9×	106 0.5×	171 1.2×	207 1.5×	22 0.2×	30	936
Koujirou Yamamoto Japan	22	267 1.2×	493 2.4×	179 1.3×	403 3.0×	24 0.2×	102	1.4k
Yukiko Kato Japan	18	319 1.4×	77 0.4×	54 0.4×	124 0.9×	28 0.2×	53	993
Yin Cheong Wong Hong Kong	20	392 1.8×	114 0.6×	163 1.2×	205 1.5×	39 0.3×	41	1.0k
Tomas Mow Denmark	14	282 1.3×	103 0.5×	39 0.3×	50 0.4×	238 2.0×	26	961
Lin Huang China	22	460 2.1×	73 0.4×	52 0.4×	189 1.4×	32 0.3×	103	1.3k

Countries citing papers authored by Alex Hemeryck

Since Specialization

Citations

This map shows the geographic impact of Alex Hemeryck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Hemeryck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Hemeryck more than expected).

Fields of papers citing papers by Alex Hemeryck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Hemeryck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Hemeryck. The network helps show where Alex Hemeryck may publish in the future.

Co-authorship network of co-authors of Alex Hemeryck

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Hemeryck. A scholar is included among the top collaborators of Alex Hemeryck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Hemeryck. Alex Hemeryck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Roy, Maarten Van, Cedric Ververken, Els Beirnaert, et al.. (2015). The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Research & Therapy. 17(1). 135–135. 145 indexed citations

Detalle, Laurent, Alex Hemeryck, Alain Vicari, et al.. (2013). pre-clinical Proof-of-concept Of Alx-0761, a Nanobody® Neutralizing Both Il-17a and F In a Cynomolgus Monkey Collagen Induced Arthritis Model. : 1287. Arthritis & Rheumatism. 65. 10 indexed citations

Roy, Maarten Van, et al.. (2012). Nonclinical safety assessment of the RANK-L targeting Nanobody® ALX-0141. Toxicology Letters. 211. S44–S44. 1 indexed citations

Vermeir, Marc, Alex Hemeryck, Filip Cuyckens, et al.. (2009). In vitro studies on the metabolism of trabectedin (YONDELIS®) in monkey and man, including human CYP reaction phenotyping. Biochemical Pharmacology. 77(10). 1642–1654. 18 indexed citations

Hemeryck, Alex, Johan Monbaliu, Tom Verhaeghe, et al.. (2007). Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib. Cancer Chemotherapy and Pharmacology. 60(6). 777–787. 42 indexed citations

Hemeryck, Alex, et al.. (2006). Pharmacokinetics, metabolism, excretion and plasma protein binding of¹⁴C-levofloxacin after a single oral administration in the Rhesus monkey. Xenobiotica. 36(7). 597–613. 18 indexed citations

Bush, Karen, Roy E. Barnewall, James E. Estep, et al.. (2006). Pharmacokinetic Considerations and Efficacy of Levofloxacin in an Inhalational Anthrax (Postexposure) Rhesus Monkey Model. Antimicrobial Agents and Chemotherapy. 50(11). 3535–3542. 39 indexed citations

Ruixo, Juan José Pérez, et al.. (2005). Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. European Journal of Pharmaceutical Sciences. 24(5). 465–475. 32 indexed citations

Ruixo, Juan José Pérez, et al.. (2004). Population pharmacokinetic analysis of pegylated human erythropoietin in rats. Journal of Pharmaceutical Sciences. 93(12). 3027–3038. 22 indexed citations

10.

Hemeryck, Alex & Frans M. Belpaire. (2002). Selective Serotonin Reuptake Inhibitors and Cytochrome P-450 Mediated Drug-Drug Interactions: An Update. Current Drug Metabolism. 3(1). 13–37. 273 indexed citations

11.

Hemeryck, Alex, et al.. (2001). Metoprolol-paroxetine interaction in human liver microsomes: stereoselective aspects and prediction of the in vivo interaction.. PubMed. 29(5). 656–63. 20 indexed citations

12.

Hemeryck, Alex, et al.. (2000). Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clinical Pharmacology & Therapeutics. 67(3). 283–291. 69 indexed citations

13.

Hemeryck, Alex, et al.. (2000). Effect of Selective Serotonin Reuptake Inhibitors on the Oxidative Metabolism of Propafenone: In Vitro Studies Using Human Liver Microsomes. Journal of Clinical Psychopharmacology. 20(4). 428–434. 20 indexed citations

14.

Hemeryck, Alex, et al.. (1999). Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes. European Journal of Clinical Pharmacology. 54(12). 947–951. 67 indexed citations

15.

Hemeryck, Alex, et al.. (1998). ECG Changes and Plasma Concentrations of Propafenone and Its Metabolites in a Case of Severe Poisoning. Journal of Toxicology Clinical Toxicology. 36(3). 247–251. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact